No. 1 Biotech Stock Pops On Unexpected Guidance Boost Amid Pandemic [Investor's Business Daily]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Investors Business Daily
Related news Vertex Pharmaceuticals ( VRTX ) handily topped first-quarter expectations Wednesday and raised its outlook for 2020 — pushing VRTX stock to pop in late action. For the first quarter ended March 31, Vertex earned $2.56 per share, excluding certain items, on $1.52 billion in sales. Both measures crushed the average estimate of analysts surveyed by Zacks Investment Research for Vertex earnings of $1.83 per share on $1.27 billion in sales. On a year-over-year basis, sales catapulted 77%. Vertex's newest cystic fibrosis treatment, a drug called Trikafta, generated $895 million in sales. Trikafta sales far outweighed Vertex's older drugs Symdeko, Orkambi and Kalydeco. Meanwhile, Vertex earnings surged 125%. Vertex credited the bullish sales increase — its best growth since March 2017 — to increased use of Trikafta in the U.S. as well as older medicines outside the U.S. following key reimbursement agreements. Trikafta is capable of treating up to 90% of patients with the debili
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- Vertex Pharmaceuticals (NASDAQ:VRTX) was given a new $564.00 price target on by analysts at Morgan Stanley.MarketBeat
- Why Analysts See Vertex Pharmaceuticals Story Shifting With New Pipeline Momentum and Valuation Debates [Yahoo! Finance]Yahoo! Finance
- Harding Loevner Global Equity's Views on Vertex Pharmaceuticals Incorporated (VRTX) [Yahoo! Finance]Yahoo! Finance
- Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today [Yahoo! Finance]Yahoo! Finance
- Vertex Pharmaceuticals' Kidney Pipeline Seen as Growth Driver, Morgan Stanley Says [Yahoo! Finance]Yahoo! Finance
VRTX
Earnings
- 11/3/25 - Beat
VRTX
Sec Filings
- 12/5/25 - Form 4
- 12/5/25 - Form 4
- 12/5/25 - Form 4
- VRTX's page on the SEC website